We are a transdisciplinary and diverse Team bringing together computer scientists, engineers, chemists, biologists, microbiologists, and various other disciplines. Our collective mission is to use the power of machines to accelerate discoveries in biology and medicine.


Explore some of our current projects:



We developed the first antibiotic designed by a computer with proven efficacy in preclinical animal models, demonstrating that machines and AI could be used to design therapeutic molecules. This breakthrough opened new avenues for using computers for antibiotic discovery. Many of our ongoing efforts focus on the use of AI for antibiotic discovery.




Our team has been in the vanguard of developing computational methods for proteome mining, leading to the discovery of a vast array of new antibiotics and significantly accelerating antibiotic discovery. We computationally mined the human proteome for the first time as a source of antibiotics. We have since mined many other proteomes across the entire Tree of Life. These efforts have dramatically reduced the time needed to discover preclinical candidates, from years to hours. This work has also revealed a new class of peptides, called encrypted peptides (EPs). EPs serve as templates for antibiotic development, and we hypothesize that they may also play a role in host immunity.





Using machine learning, our lab has discovered the first therapeutic molecules in extinct organisms, launching the field of molecular de-extinction. We believe that resurrecting molecules from the past can help address present-day problems, such as antibiotic resistance. Thus far, we have mined the proteomes of our closest relatives, Neanderthals and Denisovans, revealing a new universe of antimicrobial sequences and launching this emerging research area.






Venoms are an underappreciated source of medicines. Using structure-guided design, we have successfully reprogrammed venom-derived peptides from various creatures like wasps and frogs into potent antibiotics. These modified antibiotics have demonstrated both safety and effectiveness in preclinical mouse models. Our group has also introduced a new paradigm for treating bacterial infections through host-targeting immunotherapies, demonstrating this concept both in vitro and in animal models.







Low-cost diagnostics for bacterial and viral infections are urgently needed in low-resource settings and disadvantaged communities to control outbreaks and prevent disease spread. Current diagnostics are expensive and slow, limiting their widespread use. In response to health inequities, our lab is developing affordable diagnostic technologies. We have created several low-cost tests for COVID-19 and other emerging infectious threats. Our low-cost prototypes surpass existing tests in speed and affordability.